Clinical Resources
Materials for Providers
Alphabetical by Title
Recommendations for Pneumococcal Vaccines Use in Children and Teens
This piece gives recommendations for pneumococcal vaccines use in children and teens who are healthy or have risk factors.
Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults
Eligible healthcare professionals may vaccinate adults who meet any of the criteria on this form
Standing Orders for Administering Pneumococcal Vaccines to Children and Teens
Eligible healthcare professionals may vaccinate children or adolescents who meet any of the criteria on this form
Materials for Vaccine Recipients
Alphabetical by Title
Pneumococcus: Questions and Answers
Information about the disease and vaccines for patients and parents
Ask the Experts
CDC · FDA · State
ACIP Recommendations
Current Recommendations
ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children ― United States, 2023
MMWR. 2023 / 72(39);1072
Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
MMWR. 2023 / 72(RR-3);1–39
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2022
MMWR, September 16, 2022, 71(37);1174–1181
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
MMWR, January 28, 2022, 71 (4); 109-117
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged 65 Years and older: Updated Recommendations of the Advisory Committee on Immunization Practices
MMWR, November 22, 2019; 68(46):1069–1075
Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, September 4, 2015; 64(34):944-947
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, September 19, 2014; 63(37):822-825
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, June 28, 2013; 62(25):521-524
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, October 12, 2012; 61(40):816-9
Prevention of Pneumococcal Disease Among Infants and Children–Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine
MMWR, December 10, 2010; 59(RR11):1-18
Updated ACIP Recommendations: Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23)
MMWR, September 3, 2010; 59(34):1102-6
Additional Federal Resources
- All current and archived ACIP Pneumococcal recommendations
- General Best Practice Guidelines for Immunization
- ACIP Pneumococcal recommendations at CDC
- CDC Pneumococcal Information for Healthcare Professionals
- Summary of Who and When to Vaccinate
- PneumoRecs VaxAdvisor Mobile App for Vaccine Providers
- Pneumococcal Vaccine Timing for Adults
Vaccine Information Statements
Multi-vaccine VIS
Updated: July 24, 2023
PCV (Pneumococcal Conjugate) VIS
Updated: May 12, 2023
PPSV (Pneumococcal Polysaccharide) VIS
Updated: October 30, 2019
CDC Recommended Schedules
2024 Child and Adolescent Immunization Schedule
- Page count: 15
- Color
- Size: 8.5 ” x 11″
2024 Adult Immunization Schedule
- Page count: 13
- Color
- Size: 8.5 ” x 11″
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024
Source: The Morbidity and Mortality Weekly Report (MMWR) series prepared by CDC.
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2024
Source: The Morbidity and Mortality Weekly Report (MMWR) series prepared by CDC.
FDA Package Inserts & EUAs
Pneumococcal (PCV): Prevnar 20 Package Insert
Pfizer
Pneumococcal (PCV): Vaxneuvance (PCV15) Package Insert
Merck & Co, Inc.
Pneumococcal (PCV): Prevnar 13 Package Insert
Pfizer
Pneumococcal (PPSV): Pneumovax 23 Package Insert
Merck & Co., Inc.
State Policies
U.S. map of PCV requirements
